
The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.
Ryan Jacobs, MD discusses incidence of cardiac-related deaths among patients aged ≥65 years with B-cell malignancies treated with ibrutinib.






